Autolus Therapeutics plc
AUTL
$2.12
-$0.11-4.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -288.97M | -287.53M | -224.80M | -227.78M | -238.13M |
| Total Depreciation and Amortization | 10.24M | 9.81M | 9.26M | 8.66M | 8.19M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.20M | 46.14M | 17.32M | -2.29M | 16.23M |
| Change in Net Operating Assets | -50.79M | -51.99M | -55.96M | -41.61M | -27.60M |
| Cash from Operations | -273.32M | -283.57M | -254.18M | -263.02M | -241.32M |
| Capital Expenditure | -13.49M | -19.04M | -31.04M | -36.22M | -29.79M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 327.64M | 177.50M | -280.63M | -320.59M | -423.78M |
| Cash from Investing | 314.16M | 158.46M | -311.67M | -356.81M | -453.57M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 7.00K | 192.00K | 317.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.40M | -4.34M | 27.46M | 29.23M | 27.80M |
| Cash from Financing | -6.40M | -4.34M | 27.47M | 29.42M | 28.11M |
| Foreign Exchange rate Adjustments | 732.00K | 6.28M | -32.53M | 8.78M | 4.48M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 35.17M | -123.17M | -570.91M | -581.63M | -662.29M |